CN108576816A - 一种增加骨密度的组合物 - Google Patents
一种增加骨密度的组合物 Download PDFInfo
- Publication number
- CN108576816A CN108576816A CN201810196002.0A CN201810196002A CN108576816A CN 108576816 A CN108576816 A CN 108576816A CN 201810196002 A CN201810196002 A CN 201810196002A CN 108576816 A CN108576816 A CN 108576816A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- zinc
- magnesium
- bone density
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 230000037182 bone density Effects 0.000 title claims abstract description 50
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 52
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 48
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 48
- 239000000284 extract Substances 0.000 claims abstract description 45
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 40
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000011777 magnesium Substances 0.000 claims abstract description 33
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 33
- 235000001055 magnesium Nutrition 0.000 claims abstract description 33
- 102000008186 Collagen Human genes 0.000 claims abstract description 32
- 108010035532 Collagen Proteins 0.000 claims abstract description 32
- 229920001436 collagen Polymers 0.000 claims abstract description 32
- 239000011701 zinc Substances 0.000 claims abstract description 31
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 31
- 235000016804 zinc Nutrition 0.000 claims abstract description 31
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 30
- 239000011707 mineral Substances 0.000 claims abstract description 30
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 239000011728 vitamin K2 Substances 0.000 claims abstract description 26
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 25
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 25
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 25
- 239000011710 vitamin D Substances 0.000 claims abstract description 25
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 25
- 229940046008 vitamin d Drugs 0.000 claims abstract description 25
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 24
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 24
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 24
- 239000011718 vitamin C Substances 0.000 claims abstract description 24
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 24
- 229940046009 vitamin E Drugs 0.000 claims abstract description 24
- 239000011709 vitamin E Substances 0.000 claims abstract description 24
- 241000208689 Eucommia ulmoides Species 0.000 claims abstract description 23
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims abstract description 16
- -1 functional oligose Chemical class 0.000 claims abstract description 14
- 235000020243 first infant milk formula Nutrition 0.000 claims abstract description 13
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 claims abstract description 12
- 229940091250 magnesium supplement Drugs 0.000 claims description 32
- 235000010755 mineral Nutrition 0.000 claims description 29
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 14
- 239000011572 manganese Substances 0.000 claims description 14
- 229910052748 manganese Inorganic materials 0.000 claims description 14
- 235000013336 milk Nutrition 0.000 claims description 14
- 239000008267 milk Substances 0.000 claims description 14
- 210000004080 milk Anatomy 0.000 claims description 14
- 238000007792 addition Methods 0.000 claims description 11
- 239000003292 glue Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- 235000020985 whole grains Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000011122 softwood Substances 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical group 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- OAVRWNUUOUXDFH-UHFFFAOYSA-H 2-hydroxypropane-1,2,3-tricarboxylate;manganese(2+) Chemical compound [Mn+2].[Mn+2].[Mn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OAVRWNUUOUXDFH-UHFFFAOYSA-H 0.000 claims description 3
- 241001148782 Davallia Species 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 229960003943 hypromellose Drugs 0.000 claims description 3
- 229960001375 lactose Drugs 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 239000011656 manganese carbonate Substances 0.000 claims description 3
- 235000006748 manganese carbonate Nutrition 0.000 claims description 3
- 229940093474 manganese carbonate Drugs 0.000 claims description 3
- 239000011564 manganese citrate Substances 0.000 claims description 3
- 235000014872 manganese citrate Nutrition 0.000 claims description 3
- 229940097206 manganese citrate Drugs 0.000 claims description 3
- 239000011683 manganese gluconate Substances 0.000 claims description 3
- 235000014012 manganese gluconate Nutrition 0.000 claims description 3
- 229940072543 manganese gluconate Drugs 0.000 claims description 3
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 claims description 3
- 229910000016 manganese(II) carbonate Inorganic materials 0.000 claims description 3
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000011576 zinc lactate Substances 0.000 claims description 3
- 235000000193 zinc lactate Nutrition 0.000 claims description 3
- 229940050168 zinc lactate Drugs 0.000 claims description 3
- 239000011787 zinc oxide Substances 0.000 claims description 3
- 235000014692 zinc oxide Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical group [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 239000001755 magnesium gluconate Substances 0.000 claims description 2
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 2
- 229960003035 magnesium gluconate Drugs 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 2
- 229940099596 manganese sulfate Drugs 0.000 claims description 2
- 239000011702 manganese sulphate Substances 0.000 claims description 2
- 235000007079 manganese sulphate Nutrition 0.000 claims description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- 239000011746 zinc citrate Substances 0.000 claims description 2
- 235000006076 zinc citrate Nutrition 0.000 claims description 2
- 229940068475 zinc citrate Drugs 0.000 claims description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 2
- 229960001763 zinc sulfate Drugs 0.000 claims description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 2
- 238000005660 chlorination reaction Methods 0.000 claims 2
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 claims 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims 1
- 235000009754 Vitis X bourquina Nutrition 0.000 claims 1
- 235000012333 Vitis X labruscana Nutrition 0.000 claims 1
- 240000006365 Vitis vinifera Species 0.000 claims 1
- 235000014787 Vitis vinifera Nutrition 0.000 claims 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 claims 1
- 235000014103 egg white Nutrition 0.000 claims 1
- 210000000969 egg white Anatomy 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 239000000905 isomalt Substances 0.000 claims 1
- 235000010439 isomalt Nutrition 0.000 claims 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims 1
- 238000000465 moulding Methods 0.000 claims 1
- 239000004246 zinc acetate Substances 0.000 claims 1
- 235000013904 zinc acetate Nutrition 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 32
- 239000011575 calcium Substances 0.000 abstract description 31
- 229910052791 calcium Inorganic materials 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 10
- 230000003185 calcium uptake Effects 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 description 14
- 208000001132 Osteoporosis Diseases 0.000 description 13
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 210000002805 bone matrix Anatomy 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 239000011574 phosphorus Substances 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 7
- 108090000573 Osteocalcin Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 230000009102 absorption Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 102000004067 Osteocalcin Human genes 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000011670 zinc gluconate Substances 0.000 description 3
- 235000011478 zinc gluconate Nutrition 0.000 description 3
- 229960000306 zinc gluconate Drugs 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 2
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000008192 Lactoglobulins Human genes 0.000 description 2
- 108010060630 Lactoglobulins Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102100031475 Osteocalcin Human genes 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HZZOEADXZLYIHG-UHFFFAOYSA-N magnesiomagnesium Chemical compound [Mg][Mg] HZZOEADXZLYIHG-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 235000013557 nattō Nutrition 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 208000007442 rickets Diseases 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000012738 S100 Calcium Binding Protein G Human genes 0.000 description 1
- 108010079423 S100 Calcium Binding Protein G Proteins 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 210000001100 crypt cell Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000003552 inferior colliculi Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- KQFUCKFHODLIAZ-UHFFFAOYSA-N manganese Chemical compound [Mn].[Mn] KQFUCKFHODLIAZ-UHFFFAOYSA-N 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供一种增加骨密度的组合物，包括乳矿物盐、功能性低聚糖、维生素D、胶原蛋白、初乳碱性蛋白、维生素K2、维生素C、维生素E、镁、锌、锰、杜仲提取物和骨碎补提取物。本发明提出的增加骨密度的组合物，各成分协同作用，促进钙吸收和骨矿化，抑制钙流失和骨吸收，增加骨密度的效果显著。
Description
技术领域
本发明属于保健食品领域，具体涉及一种增加骨密度的组合物及其应用。
背景技术
骨质疏松(osteoporosis，OP)是一种以低骨量和骨组织微结构破坏为特征，导致骨质脆性增加和易于骨折的全身性骨代谢疾病。《骨质疏松症防治中国白皮书》指出，中国至少有6944万人患有骨质疏松症，有2.1亿人低骨量，存在骨质疏松症的风险，70％－80％的中老年骨折是因骨质疏松引起的，其中每年新发椎体骨折约有181万人，髋部骨折病例为23万。清华大学医院对2010-2016年发表的有关中国人骨质疏松症流行病学研究数据进行汇总研究发现，中国60岁以上人群骨质疏松症总体患病率为36％，其中男性为23％，女性为49％。随着老龄化社会的到来，骨质疏松症已成为威胁中老年人健康的高发疾病，因此，开发一款高效安全的预防骨质疏松的保健食品具有巨大的市场空间。
骨密度，是骨质量的一个重要标志，可以反映骨质疏松程度。现有的增加骨密度的保健食品主要是以补钙为主，并辅以各种促进钙吸收的相关物质，这类产品仅提高了钙的吸收率，不能解决骨钙流失和促进骨矿化的问题。因此，开发一种安全有效的增加骨密度的保健食品具有重大意义。
发明内容
为解决本领域存在的上述问题，本发明提出了一种增加骨密度的组合物。
本发明还提出所述组合物的应用。
为实现本发明上述目的的技术方案为：
一种增加骨密度的组合物，包括乳矿物盐、功能性低聚糖、维生素D、胶原蛋白、初乳碱性蛋白、维生素K2、维生素C、维生素E、镁、锌、锰、杜仲提取物和骨碎补提取物。
其中，所述功能性低聚糖是指在胃肠道内不能被消化吸收，却可以被肠中的细菌进行发酵利用的低聚糖，采用市购的功能性低聚糖即可。
其中，所述初乳碱性蛋白是以牛初乳为原料，经杀菌、脱脂、离心分离、去除酪蛋白、α－乳白蛋白、β－乳球蛋白，微滤、超滤、冷冻干燥制成，可市购；维生素K2是以大豆粉、白砂糖和葡萄糖经纳豆枯草芽孢杆菌发酵的发酵物，可市购。
进一步地，所述组合物包括以下重量份数的组分：乳矿物盐2-65份、功能性低聚糖1-35份、维生素D 0.00001-0.002份、胶原蛋白2-50份、初乳碱性蛋白0.1-10份、维生素K20.0001-0.02份、维生素C 0.1-10份、维生素E 0.005-1、镁0.2-8份、锌0.001-1份、锰0.001-0.5份、杜仲提取物0.1-12份、骨碎补提取物0.1-15份。
优选地，所述组合物包括以下重量份数的组分：乳矿物盐5-56份、功能性低聚糖4-25份、维生素D 0.00002-0.001份、鱼胶原蛋白5-40份、初乳碱性蛋白0.3-4份、维生素K20.0002-0.01份、维生素C 0.2-5份、维生素E 0.01-0.5、镁0.4-5份、锌0.005-0.6份、锰0.01-0.3份、杜仲提取物0.2-8份、骨碎补提取物0.5-10份。
更优选地，所述组合物包括以下重量份数的组分：乳矿物盐11-50份、功能性低聚糖6-16份、维生素D 0.00005-0.0005份、鱼胶原蛋白10-30份、初乳碱性蛋白0.6-1.9份、维生素K2 0.0003-0.002份、维生素C 0.5-3份、维生素E 0.03-0.3、镁0.8-2.1份、锌0.015-0.1份、锰0.02-0.1份、杜仲提取物0.5-5份、骨碎补提取物0.8-6份。
本发明优选技术方案之一为，所述镁是以硫酸镁、氯化镁、氧化镁、碳酸镁、磷酸氢镁、葡萄糖酸镁中的一种或多种复合的形式添加。
所述锌是以硫酸锌、葡萄糖酸锌、甘氨酸锌、氧化锌、乳酸锌、柠檬酸锌、氯化锌、乙酸锌、碳酸锌中的一种或多种复合的形式添加。
所述锰源是以硫酸锰、氯化锰、碳酸锰、柠檬酸锰、葡萄糖酸锰中的一种或多种复合的形式添加。
其中，所述组合物通过以下方法制备：将各组分混匀制成软材，然后制粒、干燥和整粒，制成固体制剂，所述固体制剂选自片剂、胶囊或颗粒剂。
其中，所述固体制剂中还包括制剂成型用辅料，包括木糖醇、山梨糖醇、异麦芽酮糖醇、异麦芽酮糖、甘露糖醇、淀粉、糊精、水、微晶纤维素、乳糖、羟丙甲基纤维素、磷脂、硬脂酸镁中的一种或多种。
本发明所述的增加骨密度的组合物的应用，用于制备增加骨密度的药物或用于制备预防骨质疏松的保健食品。
本发明的组合物中，
乳矿物盐100％来自牛乳，是以乳清为原料，经去除蛋白质、乳糖等成分制成，富含矿物质，主要成分是钙和磷，属于新食品原料，可以作为食品和保健食品原料使用。
功能性低聚糖具有很强的增殖肠道益生菌的功能，对双歧杆菌、乳酸菌等益生菌有高选择性增殖效果，但对大肠杆菌、肠球菌、梭状芽孢杆菌等病原菌则有明显的抑制作用，使体内微生态菌群达成平衡，这些有益菌在生长和繁殖的过程中，能够产生短链脂肪酸和免疫因子，短链脂肪酸能促进机体肠道蠕动，提高结肠渗透压，从而改善或防止便秘，免疫因子能够促进人体免疫系统的健康。此外，近期研究发现功能性低聚糖还可促进钙等矿物质的吸收，提高骨钙的含量，降低钙流失，作用机理主要有三方面：胃肠道方面：功能性低聚糖在结肠被有益菌利用，产生短链脂肪，结肠pH降低，促进钙等矿物质的增溶；肠隐窝方面：功能性低聚糖作用机体后，能够使肠道隐窝高度、每个隐窝上皮细胞的数量、盲肠血流量、粘膜-浆膜钙量(钙被动扩撒通道)增加，从而促进人体对钙的吸收；细胞方面：功能性低聚糖能够促进机体内钙结合蛋白-D9k的表达，因此激活了钙扩散通道促进钙吸收。
维生素D是人体一种必需的维生素，人体不能自行合成，需通过日晒或食物摄入获得，其主要生理功能是调节体内钙、磷代谢，维持血浆钙、磷水平，从而维持个体牙齿和骨骼的正常生长与发育。维生素D通过特异受体作用于小肠、肾和骨等靶器官：促进小肠黏膜上皮对钙、磷的吸收；促进肾近曲小管对钙、磷的重吸收；对骨有两种相反的作用：一方面,骨是人体的钙库,当血钙降低时,1,25-(OH)2D与甲状旁腺激素(parathyroid hormone,PTH)协同作用，通过破骨细胞作用,使骨盐溶解，从骨回吸收钙、磷，维持血浆钙、磷的正常浓度；另一方面，1,25-(OH)2D可促进骺板软骨和类骨组织钙化，维持钙、磷在血浆中的饱和状态有关,有利于骨盐的沉积。因此，如果维生素D缺乏,受影响最明显的就是处于快速生长期的骨骼，可导致个体罹患佝偻病或骨软化病。世界范围内维生素D不足和缺乏的发生较常见，与其相关的疾病由以往传统的骨骼畸形、骨质疏松等与骨相关的单一系统疾病延伸至癌症、自身免疫性疾病、感染性疾病、心血管疾病等多系统疾病。
胶原蛋白是骨骼的重要组成成分，骨骼是由骨基质和骨矿物质构成的复杂有机体，胶原蛋白和胶原占骨基质的1/3，骨骼的形成首先是人体吸收小分子胶原蛋白而合成胶原，胶原蛋白具有的三螺旋分子结构使胶原纤维相互交织而形成坚韧的基质网，然后利用小分子胶原蛋白中的羟脯氨酸有效地将钙、磷离子输送到骨骼中，沉积在胶原蛋白基质网上形成坚硬的骨骼。因此，胶原蛋白对骨骼形成具有至关重要的作用。
初乳碱性蛋白是以牛初乳为原料，经杀菌、脱脂、离心分离、去除酪蛋白、α-乳白蛋白、β-乳球蛋白，微滤、超滤、冷冻干燥等工艺而制成的。属于新食品原料。初乳碱性蛋白可以有效提升血清1,25-二羟基维生素D的浓度，减少尿钙的排泄，从而提高钙的利用率；还能有效降低血清BAP和TRAP的活性，并降低BGP的浓度，从而调节骨转换的速率，促进骨矿物质的沉积，使正常生成的骨基质能及时矿化，并能减少骨基质中骨矿物质的丢失；有研究表明初乳碱性蛋白可以抑制骨酸性磷酶对骨矿的水解作用，减少骨基质中骨矿物质的流失，从而达到促进骨矿化的效果。
维生素K2是经纳豆枯草芽孢杆菌发酵得到的，可以将血清中未羧化的骨钙蛋白快速转化为羧化蛋白，降低未羧化的骨钙蛋白含量，促进骨钙素的合成，显著提高血清中的骨钙素含量，增强骨矿化过程，增加骨密度；维生素K2还可以活化未羧化的骨基质蛋白(ucMGP)转化为羧化的骨基质蛋白，增加骨钙素含量，促进骨矿化和生长。此外，维生素K2还可特异性诱导破骨细胞的凋亡，并呈时间依赖性地出现凋亡细胞显著增多，并可抑制组织蛋白酶溶解骨基质，从而抑制了骨吸收。
维生素C是一种具有催化功能的小分子有机物，在人体胶原蛋白合成中发挥重要作用，
胶原蛋白占身体蛋白的1/5，用于生成结缔组织，构成身体骨架，如骨骼，血管，韧带等。
维生素E具有良好的抗氧化活性，此外还可以通过调节相关酶活性机制及调控相关基因表达机制对人体发挥作用。近期动物实验研究表明维生素E促进钙、磷代谢，增加骨矿化，对佝偻病的预防有积极作用。
镁是骨骼的组成元素，有研究发现镁还能促进骨细胞的增殖。镁是动物正常生命活动及代谢过程中许多酶系的辅助因子，适当补充镁，可以改善骨骼状态，缓解骨质疏松等。
锌是人体必需的微量元素之一，锌与多种酶、核酸、蛋白质的合成密切相关,故能维持机体的生长发育,同时能加速创伤组织愈合。儿童缺锌，会出现生长迟缓和脑垂体调节机能障碍等症状。
锰是人体必需的微量元素，对脂质代谢、硫酸软骨素和蛋白质合成起着重要作用,与结缔组织韧性、硬度、黏多糖合成、钙磷代谢密切相关,是维持骨结构、生殖中枢系统功能正常的必需元素。缺锰时软骨和骨组织生长障碍，影响骨骼健康，儿童缺锰会造成发育停滞,严重的会引起侏儒症。
杜仲和骨碎补均是传统的补肾强骨中药，中医临床上治疗骨质疏松多从补肾着手，配合健脾行气和活血化瘀，辨证施治，改善患者的临床症状。中医“肾”实质包含了下丘脑-垂体-靶腺轴等的相关作用。“补肾”一方面通过调节这些靶腺轴分泌不同的激素来调节钙磷代谢平衡，另一方面在肾小管对钙磷重吸收、肾脏分泌钙调蛋白和骨钙蛋白等在肾组织结构上面起调节作用。此外，杜仲和骨碎补还可以提高成骨细胞碱性磷酸酶活性，促进成骨细胞增值分化，抑制骨吸收，从而增加骨密度。
本发明提出的增加骨密度的组合物，各成分协同作用，促进钙吸收和骨矿化，抑制钙流失和骨吸收，增加骨密度的效果显著。
具体实施方式
以下实施例用于说明本发明，但不用来限制本发明的范围。
实施例中，如无特殊说明，所使用的方法均为本领域常规的方法。所使用的原料均为市购。
实施例1：
一种用于增加骨密度的组合物，由乳矿物盐、功能性低聚糖、维生素D、胶原蛋白、初乳碱性蛋白、维生素K2、维生素C、维生素E、镁、锌、锰、杜仲提取物、骨碎补提取物组成，各组分按重量份计为：乳矿物盐11份、功能性低聚糖6份、维生素D 0.00005份、鱼胶原蛋白10份、初乳碱性蛋白0.6份、维生素K2 0.0003份、维生素C 0.5份、维生素E 0.03份、镁0.8份(硫酸镁，加入量以有效镁计)、锌(葡萄糖酸锌，加入量以有效锌计)0.015份、锰(柠檬酸锰，加入量以有效锰计)0.02份、杜仲提取物0.5份、骨碎补提取物0.8份。
上述各组分混合混匀后制成软材，然后制粒，干燥和整粒，获得组合物1。
本实施例的原料配方，加入水、微晶纤维素、乳糖、羟丙甲基纤维素和硬脂酸镁等，按常规制备方法，可制成片剂或胶囊。
实施例2：
一种用于增加骨密度的组合物，由乳矿物盐、功能性低聚糖、维生素D、胶原蛋白、初乳碱性蛋白、维生素K2、维生素C、维生素E、镁、锌、锰、杜仲提取物、骨碎补提取物组成，各组分按重量份计，乳矿物盐13份、功能性低聚糖15份、维生素D 0.0001份、鱼胶原蛋白20份、初乳碱性蛋白1.5份、维生素K2 0.0013份、维生素C 0.8份、维生素E 0.04份、镁2份(葡萄糖酸镁，加入量以有效镁计)、锌0.04份(葡萄糖酸锌，加入量以有效锌计)、锰0.06份(柠檬酸锰，加入量以有效锰计)、杜仲提取物2份、骨碎补提取物5份。各组分混合混匀后制成软材，然后制粒，干燥和整粒，获得组合物2。
本实施例的原料配方，按常规制备方法，也可制成片剂、胶囊。
实施例3：
一种用于增加骨密度的组合物,由乳矿物盐、功能性低聚糖、维生素D、胶原蛋白、初乳碱性蛋白、维生素K2、维生素C、维生素E、镁、锌、锰、杜仲提取物、骨碎补提取物组成，各组分按重量份计，乳矿物盐21份、功能性低聚糖12份、维生素D0.0002份、鱼胶原蛋白25份、初乳碱性蛋白1份、维生素K2 0.0008份、维生素C 1份、维生素E 0.06份、镁0.9份(葡萄糖酸镁)、锌0.05份(甘氨酸锌)、锰0.04份(葡萄糖酸锰)杜仲提取物1份、骨碎补提取物1.2份。各组分混合混匀后制成软材，然后制粒，干燥和整粒，获得组合物3。
本实施例的原料配方，按常规制备方法，也可制成片剂、胶囊。
实施例4：
一种用于增加骨密度的组合物,由乳矿物盐、功能性低聚糖、维生素D、胶原蛋白、初乳碱性蛋白、维生素K2、维生素C、维生素E、镁、锌、锰、杜仲提取物、骨碎补提取物组成，各组分按重量份计，乳矿物盐32份、功能性低聚糖10份、维生素D0.0004份、鱼胶原蛋白28份、初乳碱性蛋白1.8份、维生素K2 0.001份、维生素C 2份、维生素E 0.1份、镁1.2份(磷酸氢镁)、锌0.03份(乳酸锌)、锰0.08份(碳酸锰)、杜仲提取物0.15份、骨碎补提取物3份。各组分混合混匀后制成软材，然后制粒，干燥和整粒，获得组合物4，
本实施例的原料配方，按常规制备方法，也可制成片剂或胶囊。
实施例5：
一种用于增加骨密度的组合物,由乳矿物盐、功能性低聚糖、维生素D、胶原蛋白、初乳碱性蛋白、维生素K2、维生素C、维生素E、镁、锌、锰、杜仲提取物、骨碎补提取物组成，各组分按重量份计，乳矿物盐26份、功能性低聚糖8份、维生素D 0.00006份、鱼胶原蛋白15份、初乳碱性蛋白0.8份、维生素K2 0.0004份、维生素C 1.5份、维生素E 0.2份、镁1.9份、锌0.09份、锰0.03份(原料同实施例1)、杜仲提取物2.5份、骨碎补提取物0.9份。各组分混合混匀后制成软材，然后制粒，干燥和整粒，获得组合物5，
本实施例的原料配方，按常规制备方法，也可制成片剂或胶囊。
实施例6：
一种用于增加骨密度的组合物,由乳矿物盐、功能性低聚糖、维生素D、胶原蛋白、初乳碱性蛋白、维生素K2、维生素C、维生素E、镁、锌、锰、杜仲提取物、骨碎补提取物组成，各组分按重量份计，乳矿物盐48份、功能性低聚糖14份、维生素D 0.0003份、鱼胶原蛋白8份、初乳碱性蛋白1.2份、维生素K2 0.0018份、维生素C 2.8份、维生素E 0.22份、镁1.5份、锌0.07份、锰0.09份(原料同实施例1)、杜仲提取物4.5份、骨碎补提取物5.5份。各组分混合混匀后制成软材，然后制粒，干燥和整粒，获得组合物6，
本实施例的原料配方，按常规制备方法，也可制成片剂或胶囊。
实施例7：
一种用于增加骨密度的组合物,由乳矿物盐、功能性低聚糖、维生素D、胶原蛋白、初乳碱性蛋白、维生素K2、维生素C、维生素E、镁、锌、锰、杜仲提取物、骨碎补提取物组成，各组分按重量份计，乳矿物盐50份、功能性低聚糖16份、维生素D 0.0005份、鱼胶原蛋白30份、初乳碱性蛋白1.9份、维生素K2 0.002份、维生素C 3份、维生素E 0.3份、镁2.1份、锌0.1份、锰0.1份(原料同实施例1)、杜仲提取物5份、骨碎补提取物6份。各组分混合混匀后制成软材，然后制粒，干燥和整粒，获得组合物7。
本实施例的原料配方，按常规制备方法，也可制成片剂或胶囊。
实施例8：增加骨密度实验
1.样品：本发明增加骨密度的组合物1。
2.增加骨密度实验的实验方法：参照《保健食品检验与评价技术规范》中的增加骨密度功能检验方法。
3.实验动物：雌性SD大鼠，实验前适应一周。
4.卵巢切除：大鼠经腹腔注射30mg/kgBW的戊巴比妥钠溶液麻醉后，切除双侧卵巢，术后肌肉注射2万U青霉素。大鼠卵巢切除5天后，进行阴道涂片检查，剔除卵巢切除不完全的大鼠，卵巢切除组作为模型对照组。假手术组是打开腹腔后，仅切除0.5g脂肪，保留双侧卵巢。
5.动物分组：上述去势雌性大鼠按体重随机分为模型对照组、假手术组、高剂量碳酸钙组(与样品高剂量组钙水平相同)及样品低、中、高三个剂量组。本品人体推荐量为每日6g/60kg.BW，本实验设样品低、中、高三个剂量组，即0.5g/kg.BW、1g/kg.BW、3g/kg.BW，相当于人体剂量的5倍、10倍和30倍。每组10只大鼠，单笼饲养，喂养3个月。
6.股骨骨密度测定：解剖大鼠，剥离左侧股骨，于105℃烘箱中烘干至恒重，应用骨密度仪测量大鼠股骨中点及股骨远心端骨密度。
7.骨钙测定：称量右侧股骨的总重量后，加入硝酸和高氯酸(4:1)的混合物进行消化，用原子吸收法测定骨钙含量。
8.试验数据统计：应用SPSS软件进行数据分析。
9.试验结果
从表1可以看出，假手术组的骨钙含量、中点骨密度和远心端骨密度均显著高于模型对照组，表明造成大鼠骨密度低下模型；低剂量组、中剂量组和高剂量组的骨钙含量、中点骨密度、远心端骨密度均显著高于模型对照组；中剂量组和高剂量组的骨钙含量、中点骨密度、远心端骨密度均显著高于高剂量碳酸钙组，低剂量组与高剂量碳酸钙组3个指标均无显著性差异。实验结果证明，组合物A具有增加骨密度的作用。
表1实验结果
注：同一列中的各组与模型对照组比较，*表示组间差异显著，P＜0.05；同一列中低、中、高剂量组与高剂量碳酸钙组的比较，#表示组间差异显著，P＜0.05。
此外，以实施例1中的2、3、4、5、6和7组合物进行相同的实验，结果与本实施例1中组合物1的结果相同。
上述实验结果表明，本发明组合物具有明显的增加骨密度的作用，可用于预防骨质疏松。
上述参照实施例对本发明所述的用于增加骨密度的组合物进行的详细描述，是说明性的而不是限定性的，本发明包括但不限于上述实施方式，任何符合本权利要求描述的产品，均被视为本发明的保护范围。
Claims (10)
1.一种增加骨密度的组合物，其特征在于，包括乳矿物盐、功能性低聚糖、维生素D、胶原蛋白、初乳碱性蛋白、维生素K2、维生素C、维生素E、镁、锌、锰、杜仲提取物和骨碎补提取物。
2.根据权利要求1所述的增加骨密度的组合物，其特征在于，所述组合物包括以下重量份数的组分：乳矿物盐2-65份、功能性低聚糖1-35份、维生素D 0.00001-0.002份、胶原蛋白2-50份、初乳碱性蛋白0.1-10份、维生素K2 0.0001-0.02份、维生素C 0.1-10份、维生素E0.005-1、镁0.2-8份、锌0.001-1份、锰0.001-0.5份、杜仲提取物0.1-12份、骨碎补提取物0.1-15份。
3.根据权利要求2所述的增加骨密度的组合物，其特征在于，所述组合物包括以下重量份数的组分：乳矿物盐5-56份、功能性低聚糖4-25份、维生素D 0.00002-0.001份、鱼胶原蛋白5-40份、初乳碱性蛋白0.3-4份、维生素K2 0.0002-0.01份、维生素C 0.2-5份、维生素E0.01-0.5、镁0.4-5份、锌0.005-0.6份、锰0.01-0.3份、杜仲提取物0.2-8份、骨碎补提取物0.5-10份。
4.根据权利要求3所述的增加骨密度的组合物，其特征在于，所述组合物包括以下重量份数的组分：乳矿物盐11-50份、功能性低聚糖6-16份、维生素D 0.00005-0.0005份、鱼胶原蛋白10-30份、初乳碱性蛋白0.6-1.9份、维生素K2 0.0003-0.002份、维生素C 0.5-3份、维生素E 0.03-0.3、镁0.8-2.1份、锌0.015-0.1份、锰0.02-0.1份、杜仲提取物0.5-5份、骨碎补提取物0.8-6份。
5.根据权利要求1所述的增加骨密度的组合物，其特征在于，所述镁是以硫酸镁、氯化镁、氧化镁、碳酸镁、磷酸氢镁、葡萄糖酸镁中的一种或多种复合的形式添加。
6.根据权利要求1所述的增加骨密度的组合物，其特征在于，所述锌是以硫酸锌、葡萄糖酸锌、甘氨酸锌、氧化锌、乳酸锌、柠檬酸锌、氯化锌、乙酸锌、碳酸锌中的一种或多种复合的形式添加。
7.根据权利要求1所述的增加骨密度的组合物，其特征在于，所述锰是以硫酸锰、氯化锰、碳酸锰、柠檬酸锰、葡萄糖酸锰中的一种或多种复合的形式添加。
8.根据权利要求1～7任一项所述的增加骨密度的组合物，其特征在于，所述组合物通过以下方法制备：将各组分混匀制成软材，然后制粒、干燥和整粒，制成固体制剂，所述固体制剂为片剂、胶囊或颗粒剂。
9.根据权利要求8所述的增加骨密度的组合物，其特征在于，所述固体制剂中还包括制剂成型用辅料，包括木糖醇、山梨糖醇、异麦芽酮糖醇、异麦芽酮糖、甘露糖醇、淀粉、糊精、水、微晶纤维素、乳糖、羟丙甲基纤维素、磷脂、硬脂酸镁中的一种或多种。
10.权利要求1～9任一项所述的增加骨密度的组合物的应用，其特征在于，用于制备增加骨密度的药物或用于制备预防骨质疏松的保健食品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810196002.0A CN108576816A (zh) | 2018-03-09 | 2018-03-09 | 一种增加骨密度的组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810196002.0A CN108576816A (zh) | 2018-03-09 | 2018-03-09 | 一种增加骨密度的组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108576816A true CN108576816A (zh) | 2018-09-28 |
Family
ID=63625917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810196002.0A Pending CN108576816A (zh) | 2018-03-09 | 2018-03-09 | 一种增加骨密度的组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108576816A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111569052A (zh) * | 2020-06-30 | 2020-08-25 | 汤臣倍健股份有限公司 | 一种增加更年期妇女骨密度的组合物及其保健品、应用 |
| CN113558247A (zh) * | 2021-08-03 | 2021-10-29 | 汤臣倍健股份有限公司 | 一种含有高含量乳矿物盐成分的片剂的制备方法 |
| CN113729230A (zh) * | 2020-05-29 | 2021-12-03 | 安琪纽特股份有限公司 | 预防骨质疏松或增强骨密度的组合物及其制备和应用 |
| CN115777785A (zh) * | 2022-11-15 | 2023-03-14 | 爱齐匹奥有限公司 | 用于促进骨形成或预防骨流失组合物 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251671A (zh) * | 2012-12-28 | 2013-08-21 | 北京中研同仁堂医药研发有限公司 | 一种增加骨密度的含中药的组合物及其制备方法 |
| CN104721230A (zh) * | 2015-04-13 | 2015-06-24 | 福州乾正药业有限公司 | 乳碱性蛋白与乳矿物盐的组合物及其制备方法和应用 |
| CN105145846A (zh) * | 2015-10-27 | 2015-12-16 | 江西美庐乳业集团有限公司 | 一种提高骨密度，改善骨质疏松的营养包 |
| CN105533712A (zh) * | 2015-12-29 | 2016-05-04 | 天津天狮生物发展有限公司 | 用于增加骨密度并且增强免疫力的组合物 |
| CN105996059A (zh) * | 2016-06-15 | 2016-10-12 | 天津天狮生物发展有限公司 | 一种用于增加骨密度的组合物 |
| CN107581608A (zh) * | 2017-09-22 | 2018-01-16 | 张丽艳 | 一种增加骨密度的胶囊制剂及其制备方法 |
-
2018
- 2018-03-09 CN CN201810196002.0A patent/CN108576816A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251671A (zh) * | 2012-12-28 | 2013-08-21 | 北京中研同仁堂医药研发有限公司 | 一种增加骨密度的含中药的组合物及其制备方法 |
| CN104721230A (zh) * | 2015-04-13 | 2015-06-24 | 福州乾正药业有限公司 | 乳碱性蛋白与乳矿物盐的组合物及其制备方法和应用 |
| CN105145846A (zh) * | 2015-10-27 | 2015-12-16 | 江西美庐乳业集团有限公司 | 一种提高骨密度，改善骨质疏松的营养包 |
| CN105533712A (zh) * | 2015-12-29 | 2016-05-04 | 天津天狮生物发展有限公司 | 用于增加骨密度并且增强免疫力的组合物 |
| CN105996059A (zh) * | 2016-06-15 | 2016-10-12 | 天津天狮生物发展有限公司 | 一种用于增加骨密度的组合物 |
| CN107581608A (zh) * | 2017-09-22 | 2018-01-16 | 张丽艳 | 一种增加骨密度的胶囊制剂及其制备方法 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113729230A (zh) * | 2020-05-29 | 2021-12-03 | 安琪纽特股份有限公司 | 预防骨质疏松或增强骨密度的组合物及其制备和应用 |
| CN111569052A (zh) * | 2020-06-30 | 2020-08-25 | 汤臣倍健股份有限公司 | 一种增加更年期妇女骨密度的组合物及其保健品、应用 |
| CN113558247A (zh) * | 2021-08-03 | 2021-10-29 | 汤臣倍健股份有限公司 | 一种含有高含量乳矿物盐成分的片剂的制备方法 |
| CN113558247B (zh) * | 2021-08-03 | 2022-05-31 | 汤臣倍健股份有限公司 | 一种含有高含量乳矿物盐成分的片剂的制备方法 |
| CN115777785A (zh) * | 2022-11-15 | 2023-03-14 | 爱齐匹奥有限公司 | 用于促进骨形成或预防骨流失组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108576816A (zh) | 一种增加骨密度的组合物 | |
| KR100813914B1 (ko) | 장내 생균제 공동-발효 배양물에 의한 천연 의약의 전환과변형 | |
| CN107691838B (zh) | 宠物绝育缓释膏及其制备方法 | |
| CN109984269A (zh) | 一种具有补钙和保持关节健康的宠物营养膏及制备方法 | |
| CN110720516A (zh) | 骨营养特膳食品及其制备方法和应用 | |
| CN104605226A (zh) | 一种具有增加骨密度功能的保健品 | |
| CN114042146B (zh) | 一种牛骨肽组合物及其在制备调节肠道菌群及防治骨质疏松药物中的应用 | |
| JP4132635B2 (ja) | 未失活酵素強化組成物 | |
| CN109432388B (zh) | 一种益生菌和盐酸氨基葡萄糖的组合物及其在骨关节健康方面的应用 | |
| CN104824677A (zh) | 一种增加骨密度的保健食品及其制备方法 | |
| CN109170916A (zh) | 一种强身健体食品组合物及其制备方法 | |
| CN108159199A (zh) | 一种复合菌种发酵的益母增蛋散的制备方法 | |
| CN107929721A (zh) | 一种具有促进青少年骨骼生长和增高功效的配方产品 | |
| CN101647816A (zh) | 一种动物皮类的酶解产物及其用途 | |
| CN113082059B (zh) | 一种防治骨质疏松症的组合物及其制备方法和应用 | |
| CN109601880B (zh) | 一种增加骨密度的保健食品 | |
| CN105920606A (zh) | 一种用于治疗小儿腹泻病的复方口服液及其制备方法 | |
| WO2018107324A1 (zh) | 一种降低了高钙血风险的补钙组合物及其应用 | |
| CN115297878A (zh) | 用于增强人受试者中尿石素产生的组合物 | |
| CN115005384A (zh) | 一种具有补钙功效的酶解骨粉制备方法 | |
| CN104587456A (zh) | 一种增加骨密度的保健品的制作工艺 | |
| CN103494201B (zh) | L-抗坏血酸棕榈酸酯配伍的骨关节疾病保健品 | |
| CN109223826A (zh) | 一种复方维生素钙片剂 | |
| CN109172804A (zh) | 一种提高精子活性、改善不孕不育的组合物及其制备方法 | |
| CN116711862B (zh) | 一种提高骨密度的组合物及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |